Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2023-01-04 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
전환가액의조정(제2회차 CB)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price of convertible bonds (CB) due to a decline in market price. This type of disclosure relates to changes in the company's capital structure and financial instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most appropriate as it covers updates on financing activities and capital structure changes, including adjustments to convertible debt terms.
2023-01-04 Korean
조회공시요구(풍문또는보도)에대한답변(미확정)
Regulatory Filings Classification · 100% confidence The document is a regulatory response to a 'request for disclosure' (조회공시 요구) regarding market rumors about a KOSDAQ listing. It is a standard regulatory filing in the Korean market where a company provides an update on the status of a pending corporate action (in this case, 'undetermined'). Since it does not fit into specific categories like M&A, dividends, or financial reports, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2023-01-02 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory notice regarding the setting of a record date for the purpose of holding an Annual General Meeting (AGM). It does not contain the full AGM materials or proxy statements, but rather serves as a formal regulatory announcement of the meeting preparation. Given the nature of the announcement regarding shareholder rights and meeting preparation, it fits best under the general regulatory filing category.
2022-12-16 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding changes of Tiger Asset Management in Ensol Biosciences. This falls under the category of Major Shareholding Notification as it tracks significant ownership levels and changes.
2022-12-09 Korean
전환가액의조정(제3회차 CB)
Share Issue/Capital Change Classification · 100% confidence The document is an official regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in market price. This type of disclosure, which details changes to capital structure instruments like convertible debt, falls under the 'Capital/Financing Update' category.
2022-12-09 Korean
조회공시요구(풍문또는보도)에대한답변(미확정)
Regulatory Filings Classification · 100% confidence The document is a formal response to a regulatory inquiry (조회공시 요구) regarding market rumors about a KOSDAQ listing. It is a standard regulatory disclosure document issued by the company to address market speculation and provide updates on corporate status. Since it does not fit into specific categories like M&A, financial reports, or director dealings, it falls under the general regulatory filing category.
2022-12-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.